FutureGen Industries从2025年出售三家生物技术公司的股份中赚取了105万美元。 
FutureGen Industries earned $1.05 million from selling shares in three biotech firms in 2025.
FutureGen Industries报告,2025年销售三家生命科学公司股份的收益很大:加拿大生物技术发展癌症疗法的Onco创新有限公司765 065.33美元;ASEP医疗控股公司118 255.57美元,其重点是抗生素感染的败血症诊断和治疗;Core One Labs公司167 473.19美元,该公司是精神医学开发商,拥有专利的psilocybin系统和符合GMP标准的设施。 FutureGen Industries reported substantial 2025 gains from selling shares in three life sciences companies: $765,065.33 from Onco-Innovations Limited, a Canadian biotech developing cancer therapies; $118,255.57 from ASEP Medical Holdings Inc., which focuses on sepsis diagnostics and treatments for antibiotic-resistant infections; and $167,473.19 from Core One Labs Inc., a psychedelic medicine developer with proprietary psilocybin systems and GMP-compliant facilities. 结果反映了该公司在高潜力生物技术企业中的战略投资。 The results reflect the company’s strategic investments in high-potential biotech ventures.
